Shared predispositions of Parkinsonism and cancer: A population-based pedigree-linked study

Archives of Neurology

Volumn 69, Issue 12, 2012, Pages 1572-1577

  Kareus, Seth A ^a   Figueroa, Karla P ^a   Cannon Albright, Lisa A ^a   Pulst, Stefan M ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; BIRTHPLACE; BRONCHUS CANCER; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CAUSE OF DEATH; COLORECTAL CANCER; DEATH CERTIFICATE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENETIC LINKAGE; HUMAN; LUNG CANCER; MELANOMA; NEOPLASM; PANCREAS CANCER; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RELATIVE; SEX; STOMACH CANCER; UNITED STATES;

EID: 84871243120     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.2261     Document Type: Article

References (41)

1. Pan T, Li X, Jankovic J. The association between Parkinson's disease and melanoma. Int J Cancer. 2011;128(10):2251-2260.
2. Paisán-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology. 2010;75(18):1653-1655.
3. Ferreira JJ, Neutel D, Mestre T, et al. Skin cancer and Parkinson's disease. Mov Disord. 2010;25(2):139-148.
4. Møller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson's disease. BMJ. 1995;310(6993):1500-1501.
5. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Møller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer. 2005;92(1):201-205. (Pubitemid 40188456)
6. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1260-1265. (Pubitemid 46984968)
7. Inzelberg R, Israeli-Korn SD. The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers. J Neural Transm. 2009;116(11):1503-1507.
8. Bertoni JM, Arlette JP, Fernandez HH, et al North American Parkinson's and Melanoma Survey Investigators. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol. 2010;67(3):347-352.
9. Skibba JL, Pinckley J, Gilbert EF, Johnson RO. Multiple primary melanoma following administration of levodopa. Arch Pathol. 1972;93(6):556-561.
10. Pfützner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? two new cases and a review of the literature. J Am Acad Dermatol. 1997;37(2, pt 2):332-336. (Pubitemid 27350006)
11. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord. 2003;9(6):321-327. (Pubitemid 36809033)
12. Constantinescu R, Romer M, Kieburtz K; DATATOP Investigators of the Parkinson Study Group. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord. 2007;22(5):720-722. (Pubitemid 46800147)
13. Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Mov Disord. 2007;22(9):1252-1257. (Pubitemid 47325031)
14. Baade PD, Fritschi L, Freedman DM. Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients. Neuroepidemiology. 2007;28(1):16-20. (Pubitemid 46221024)
15. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009;73(16):1286-1291.
16. Olsen JH, Jørgensen TL, Rugbjerg K, Friis S. Parkinson disease and malignant melanoma in first-degree relatives of patients with early-onset melanoma. Epidemiology. 2011;22(1):109-112.
17. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21(5):697-707.
18. US Food and Drug Administration. FDA drug safety communication: ongoing safety review of Stalevo (entacapone/carbidopa/levodopa) and possible development of prostate cancer. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm206363.htm. Accessed May 2012.
19. Skolnick M. The Utah genealogical data base: a resource for genetic epidemiology. In: Cairns J, Lyon JL, Skolnick M, eds. Banbury Report No 4: Cancer Incidence in Defined Populations. New York, New York: Cold Spring Harbor Laboratory; 1980:285-297.
20. University of Utah. Utah Cancer Registry. http://ucr.utah.edu/. Accessed May 2012.
21. Albright FS, Orlando P, Pavia AT, Jackson GG, Cannon Albright LA. Evidence for a heritable predisposition to death due to influenza. J Infect Dis. 2008;197(1):18-24. (Pubitemid 351263461)
22. Teerlink CC, Hegewald MJ, Cannon-Albright LA. A genealogical assessment of heritable predisposition to asthma mortality. Am J Respir Crit Care Med. 2007;176(9):865-870. (Pubitemid 350097075)
23. Weires MB, Tausch B, Haug PJ, Edwards CQ, Wetter T, Cannon-Albright LA. Familiality of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007;115(10):634-640. (Pubitemid 350220402)
24. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011;76(23):2002-2009.
25. Pressley JC, Tang MX, Marder K, Cote LJ, Mayeux R. Disparities in the recording of Parkinson's disease on death certificates. Mov Disord. 2005;20(3):315-321. (Pubitemid 40613292)
26. Centers for Disease Control and Prevention. Leading causes of death. http://www.cdc.gov/nchs/fastats/lcod.htm. Accessed May 2012.
27. Jorde LB. Inbreeding in the Utah Mormons: an evaluation of estimates based on pedigrees, isonymy, and migration matrices. Ann Hum Genet. 1989;53(pt 4):339-355. (Pubitemid 19282107)
28. McLellan T, Jorde LB, Skolnick MH. Genetic distances between the Utah Mormons and related populations. Am J Hum Genet. 1984;36(4):836-857. (Pubitemid 14030098)
29. Centers for Disease Control and Prevention. Skin cancer rates by state. http://www.cdc.gov/cancer/skin/statistics/state.htm. Accessed May 2012.
30. Centers for Disease Control and Prevention. Adult cigarette smoking in the United States: current estimate. http://www.cdc.gov/tobacco/data-statistics/ fact-sheets/adult-data/cig-smoking/index.htm. Accessed May 2012.
31. Shishido T, Ikemura M, Obi T, et al. Alpha-synuclein accumulation in skin nerve fibers revealed by skin biopsy in pure autonomic failure. Neurology. 2010;74(7):608-610.
32. Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol. 2010;120(1):1-12.
33. Matsuo Y, Kamitani T. Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One. 2010;5(5):e10481.
34. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608. (Pubitemid 28207717)
35. Cesari R, Martin ES, Calin GA, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A. 2003;100(10):5956-5961. (Pubitemid 36581860)
36. Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res. 1991;51(20):5449-5453.
37. Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7(3):263-273. (Pubitemid 40568685)
38. Di Fonzo A, Rohé CF, Ferreira J, et al Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005;365(9457):412-415. (Pubitemid 40179228)
39. Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet. 2009;41(8):920-925.
40. Elbaz A, Peterson BJ, Yang P, et al. Nonfatal cancer preceding Parkinson's disease: a case-control study. Epidemiology. 2002;13(2):157-164. (Pubitemid 34160490)
41. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18-27.